HIGHLIGHTS
- who: Fabiola Vacca and colleagues from the Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy have published the paper: Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering Approaches for Enhanced Effector Functions, in the Journal: Biomedicines 2022, 10, 2126. of /2022/
- what: One of the main reasons for clinical trial failure of anti-bacterial mAbs is the difficulty in translating results from in_vivo tests to clinical trials.
- future: Various pathogens are acquiring resistance mechanisms inhibiting any chance of success of antibiotics and thus may become critically untreatable in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.